Advertisement

BNGO

Bionano Genomics, Inc.

Healthcare · USD

Set alert

Price alert · BNGO

All alert types
1.15 USD -0.05 -4.17%
As of Oct 30, 2026 Extended hours 1.19 +3.48%
Bid
1.15 × 1
Ask
1.16 × 1
1.12 Day range 1.20
1.06 52-week range 1.85
YTD
-24.84%
1 year
-35.75%
Open
1.20
Prev close
1.20
Mkt cap
16.07M
Vol
196.43K
Avg vol
945.92K
EPS
-3.02
P/E
0.00
Div yield
0.00%
More statistics
Low
1.12
High
1.20
Forward P/E
-0.41
Beta
2.38
Short ratio
3.81
Inst. own
12.81%
Dividend
0.00
Ex-div date
Earnings
Aug 7, 2024
50-d avg
0.2652
200-d avg
0.6133
1y target
1.00

5D chart

Chart tools
Interval
BNGO five-day price chart1.101.141.181.211.25Oct 23Oct 26Oct 27Oct 28Oct 29

Key statistics

Market cap
20.64M
Enterprise value
30.64M
Trailing P/E
0.00
Forward P/E
-0.41
PEG ratio
0.00
Price / sales
0.56
Price / book
0.10
EPS (TTM)
-2.30
Beta
2.38
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
36.58M
Revenue growth
-10.30%
Free cash flow
-55.98M
Total cash
18.94M
Total debt
27.57M
Return on equity
-138.33%
Shares outstanding
101.99M
Short % of float
10.26%
50-day average
0.2652
200-day average
0.6133

Analyst view

Consensus: none

Price target (mean) 1.00
Ratings (0m) 4 0 buy · 4 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Aug 7, 2024

Expected Aug 7, 2024. Consensus EPS estimate -0.14.

Earnings history

Financials — quick view

All financials
BNGO Revenue — quarterly 8.17M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BNGO Net income — quarterly -7.42M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BNGO EPS — quarterly -0.64
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

BNGO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 14, 2024Sep 1, 20240.00-0.32——
Aug 7, 2024Jun 1, 20240.00-0.24——
Aug 7, 2024Jun 1, 20240.00———
May 8, 2024Mar 1, 20240.00-0.60——
May 8, 2024Mar 1, 20240.00———
Mar 5, 2024Dec 1, 20230.00-0.96——

Upgrades / downgrades

BNGO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 15, 2024Ladenburg ThalmanndownBuyNeutral
May 16, 2024BTIGmainBuyBuy
Mar 7, 2024ScotiabankmainSector OutperformSector Outperform
Nov 13, 2023Maxim GroupdownBuyHold
Aug 10, 2023BTIGmainBuyBuy

About Bionano Genomics, Inc.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
bionano.com

News

Your note

Sign in to keep a note on BNGO — it syncs with the Stock Master app.

Insider holders

BNGO insider holders
InsiderRelationLatest transactionDateShares held
CHAUBEY ALKA PH.D.OfficerStock Award(Grant)Jun 2, 202448,245
DIXON JONATHAN VGeneral CounselStock Award(Grant)Jun 2, 202418,025
HOLMLIN R ERIKChief Executive OfficerStock Award(Grant)Jun 2, 2024122,315
KAMA GULSENChief Financial OfficerStock Award(Grant)Jun 2, 202416,000
MAMUSZKA HANNAHDirectorPurchaseJun 12, 202365,789
OLDAKOWSKI MARKChief Operating OfficerStock Award(Grant)Jun 2, 202464,698

Institution ownership

BNGO institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc2.15%2,192,492443.76KSep 29, 2024
Geode Capital Management, LLC0.87%882,854178.69KSep 29, 2024
Blackrock Inc.0.60%614,163124.31KSep 29, 2024
GMT Capital Corp0.52%530,260107.32KSep 29, 2024
Citadel Advisors Llc0.24%249,07050.41KSep 29, 2024
Northern Trust Corporation0.14%147,13429.78KSep 29, 2024

Fund ownership

BNGO fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.34%1,364,438276.16KSep 29, 2024
Vanguard Extended Market Index Fund0.50%505,292102.27KSep 29, 2024
Fidelity Extended Market Index Fund0.48%492,06099.59KOct 30, 2024
Vanguard Health Care Index Fund0.20%208,60142.22KAug 30, 2024
Fidelity Total Market Index Fund0.16%166,23433.65KOct 30, 2024
Fidelity Series Total Market Index Fund0.11%116,33123.55KOct 30, 2024
Advertisement